YM-215389 and YM-228855 are thiazolidenebenzenesulfonamide (TBS) derivatives and novel non-nucleoside reverse transcriptase inhibitors (NNRTIs) that inhibit not only wild-type, but also the K103N- and Y181C-substituted reverse transcriptase (RT) of HIV type-1 (HIV-1).
Methods:
To characterize the binding modes of the TBS derivatives in detail, the anti-HIV-1 activities of YM-215389 and YM-228855 against various NNRTI-resistant clones were examined. Docking studies with HIV-1 RT were also performed.
Results:
YM-215389, which effectively inhibits various NNRTI-resistant clones, interacted with L100, K103, V106 and Y318 through the benzene ring and with E138, V179, Y181, Y188 and W229 through the thiazole ring. A single amino acid substitution confers only moderate resistance to YM-215389; indeed, four amino acid substitutions (V106L, V108I, E138K and L214F) were necessary for high- level resistance. Although the activity of YM-228855, a derivative of YM-215389 that has two bulky and rigid cyano-moieties on the benzene ring, was 10x more potent against HIV-1 than YM-215389, its anti-HIV-1 activity was readily reduced with single substitutions as with Y181I and K103N.
Conclusions:
These results provide structural information for optimizing the TBS derivatives in an attempt to construct ideal NNRTIs that maintain anti-HIV-1 activity to various HIV-1 variants.
References
1.
TantilloCDingJJacobo-MolinaA. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol1994; 243: 369–387.
2.
MitchlaZSharlandM. Current treatment options to prevent perinatal transmission of HIV. Expert Opin Pharmacother2000; 1: 239–248.
3.
LallemantMJourdainGLe CoeurS. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med2004; 351: 217–228.
StaszewskiSMorales-RamirezJTashimaKT. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med1999; 341: 1865–1873.
6.
LucasGMChaissonREMooreRD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS2001; 15: 1679–1686.
7.
RobbinsGKDe GruttolaVShaferRW. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med2003; 349: 2293–2303.
8.
GulickRMRibaudoHJShikumaCM. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med2004; 350: 1850–1861.
9.
HsiouYDingJDasK. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. J Mol Biol2001; 309: 437–445.
10.
RichmanDD, ACTG 164/168 Study Team. Loss of nevirapine activity associated with emergence of resistance in clinical trials. VIII International Conference on AIDS/III STD World Congress. 19–24 July 1992, Amsterdam, the Netherlands. Abstract PoB 3576.
11.
RichmanDDShihC-KLowyI. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A1991; 88: 11241–11245.
12.
BachelerLJeffreySHannaG. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol2001; 75: 4999–5008.
13.
BachelerLTAntonEDKudishP. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother2000; 44: 2475–2484.
14.
MasudaNYamamotoOFujiiM. Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. Bioorg Med Chem2005; 13: 949–961.
15.
FujiwaraMIjichiKHanasakiY. Thiadiazole derivatives: Highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro. Microbiol Immunol1997; 41: 301–308.
16.
FujiwaraMKodamaENOkamotoM. Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4–2217. Antivir Chem Chemother1999; 10: 315–320.
17.
MasudaNYamamotoOFujiiM. Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. Bioorg Med Chem2004; 12: 6171–6182.
18.
KimptonJEmermanM. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol1992; 66: 2232–2239.
19.
KodamaEIKohgoSKitanoK. 4′-Ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother2001; 45: 1539–1546.
20.
NamekiDKodamaEIkeuchiM. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Revresponsive element functions. J Virol2005; 79: 764–770.
21.
ShimuraKKodamaESakagamiY. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol2008; 82: 764–774.
22.
JonesGWillettPGlenRC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol1995; 245: 43–53.
23.
BermanHMWestbrookJFengZ. The Protein Data Bank. Nucleic Acids Res2000; 28: 235–242.
RenJMiltonJWeaverKLShortSAStuartDIStammersDK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Des2000; 8: 1089–1094.
26.
AllenFH. The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Crystallogr B2002; 58: 380–388.
27.
KantorRMacHekanoRGonzalesMJDupnikKSchapiroJMShaferRW. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: An expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res2001; 29: 296–299.
ClarkSACalefCMellorsJW. Mutations in retroviral genes associated with drug resistance. In HIV Sequence Compendium 2005. Edited by LeitnerTHahnBMarxPMcCutchanFMellorsJWolinskyS & KorberB. New Mexico: Los Alamos National Laboratory2005; pp. 80–174.
30.
ParikhUCalefCClarkSAMellorsJW. Mutations in retroviral genes associated with drug resistance. In HIV Sequence Compendium 2003. Edited by LeitnerTHahnBMarxPMcCutchanFMellorsJWolinskyS & KorberB. New Mexico: Los Alamos National Laboratory2003; pp. 38–122.
31.
BalzariniJKleimJPRiessGCamarasaMJDe ClercqEKarlssonA. Sensitivity of (138 Glu->Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem Biophys Res Commun1994; 201: 1305–1312.
32.
SchinaziRFLarderBAMellorsJW. Mutations in retroviral genes associated with drug resistance: 1999–2000 update. Int Antiviral News1999; 7: 46–69.
33.
DingJDasKMoereelsH. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol1995; 2: 407–415.
34.
RenJEsnoufRGarmanE. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol1995; 2: 293–302.
35.
SmerdonSJJagerJWangJ. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A1994; 91: 3911–3915.
36.
KohlstaedtLAWangJFriedmanJMRicePASteitzTA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science1992; 256: 1783–1790.
37.
EsnoufRRenJRossCJonesYStammersDStuartD. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol1995; 2: 303–308.
38.
SpenceRAKatiWMAndersonKSJohnsonKA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science1995; 267: 988–993.
39.
DasKLewiPJHughesSHArnoldE. Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol2005; 88: 209–231.
40.
DasKClarkADJrLewiPJ. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem2004; 47: 2550–2560.
41.
PalmerSMargotNGilbertHShawNBuckheitRJrMillerM. Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B-subtypes or nucleoside resistance. AIDS Res Hum Retroviruses2001; 17: 1167–1173.
42.
SrinivasRVFridlandA. Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains. Antimicrob Agents Chemother1998; 42: 1484–1487.
43.
TuskeSSarafianosSGClarkADJr. Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir. Nat Struct Mol Biol2004; 11: 469–474.
44.
YoshimuraKKatoRYusaK. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci U S A1999; 96: 8675–8680.
